— Avid Bioservices (NASDAQ: CDMO) reported a second-quarter 2020 loss of $0.03 per share versus a loss of $0.05 per share expected.
— Revenue soared by 80% to $18.3 million versus $14.25 million expected. This was driven by an increase in the number of in-process and completed manufacturing runs as a result of growing demand from a more diversified client base.
— As of October 31, 2019, revenue backlog was about $52 million, a decrease of 16% as compared to the first quarter of fiscal 2020. The company expects to recognize the majority of this backlog within the next twelve months.
— The gross margin increased to 18% from 3% in the prior-year quarter. This was primarily attributed to the increased number of manufacturing runs.
— Looking ahead into fiscal 2020, the company confirmed its revenue outlook in the range of $64 million to $67 million. In contrast, analysts expect revenue of $65.38 million for the full year.
— The company launched expanded process development (PD) facilities and services. Also, it expanded the scope of work with multiple existing customers to increase the number of manufacturing batches and/or scale of production.
Most Popular
Abbott Laboratories (ABT) Q2 2025 sales and earnings beat estimates
Abbott Laboratories (NYSE: ABT) on Thursday announced financial results for the second quarter of fiscal 2025, reporting an increase in sales and adjusted profit. The results also exceeded Wall Street's
US Bancorp (USB) Earnings: 2Q25 Key Numbers
US Bancorp (NYSE: USB) reported its second quarter 2025 earnings results today. Total net revenue increased 2% year-over-year to $7 billion. Net income applicable to US Bancorp common shareholders rose
Key highlights from GE Aerospace’s (GE) Q2 2025 earnings results
GE Aerospace (NYSE: GE) reported its second quarter 2025 earnings results today. Total revenue increased 21% year-over-year to $11 billion. Adjusted revenue grew 23% to $10.1 billion. Net income attributable to
Comments
Comments are closed.